Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
10h agoAbbVie Inc. raises guidance after strong Q3 performance
AbbVie announced its third-quarter results for the period ended September 30, 2025, highlighting strong momentum across key medicine portfolios. While oncology and aesthetics revenues declined slightly, the company raised its full-year adjusted EPS guidance to US$10.61–10.65 per share, up from US$10.38–10.58. It also announced a dividend increase of 5.5% for 2026. Despite near-term headwinds in some segments, management pointed to innovation and a robust pipeline as drivers for long-term growth.
positive
10h agoAbbVie Inc. raises guidance after strong Q3 performance
AbbVie announced its third-quarter results for the period ended September 30, 2025, highlighting strong momentum across key medicine portfolios. While oncology and aesthetics revenues declined slightly, the company raised its full-year adjusted EPS guidance to US$10.61–10.65 per share, up from US$10.38–10.58. It also announced a dividend increase of 5.5% for 2026. Despite near-term headwinds in some segments, management pointed to innovation and a robust pipeline as drivers for long-term growth.
positive
AbbVie Inc. raises guidance after strong Q3 performance
about 10 hours ago
1 min read
70 words
AbbVie raised full-year EPS guidance after a strong Q3 showing, signalling confidence in its pipeline despite some revenue dips.
AbbVie announced its third-quarter results for the period ended September 30, 2025, highlighting strong momentum across key medicine portfolios. While oncology and aesthetics revenues declined slightly, the company raised its full-year adjusted EPS guidance to US$10.61–10.65 per share, up from US$10.38–10.58. It also announced a dividend increase of 5.5% for 2026. Despite near-term headwinds in some segments, management pointed to innovation and a robust pipeline as drivers for long-term growth.
AbbVie announced its third-quarter results for the period ended September 30, 2025, highlighting strong momentum across key medicine portfolios. While oncology and aesthetics revenues declined slightly, the company raised its full-year adjusted EPS guidance to US$10.61–10.65 per share, up from US$10.38–10.58. It also announced a dividend increase of 5.5% for 2026. Despite near-term headwinds in some segments, management pointed to innovation and a robust pipeline as drivers for long-term growth.
Tags:
stocks
global
stocks
global
pharma
earnings
guidance
Oct 31, 2025 • 13:37 IST